Related to GE Healthcare Partners with Japan’s Clino on Tau Protein PET Agent for Alzheimer Disease

• ImaginAb Raises $12.5M for Antibody Fragment PET Imaging Platform
  
• GE Healthcare, Dyax to Develop c-Met Imaging Peptides for Cancer
  
• GE Snags Sequencing Services Firm SeqWright
  
• FDA Clears Avid’s Amyloid Plaque Imaging Agent for Aiding Alzheimer Disease Diagnosis
  
• Nuron Gains Preclinical Alzheimer Vaccine from Vitruvian BioMedical
  
• GE Healthcare Supplies Refine Tech with Filtration Cartridges for ATF Cell Retention System
  
• With Acquisition of Bayer Imaging R&D Portfolio, Piramal Continues Shift to Pharma IP
  
• Oligomerix Raises $2M for Tau Protease Inhibitor Alzheimer Disease Program
  
• Scientists Synthesize Spin-Labeled Fluorene as Potential Alzheimer Therapeutic, Diagnostic
  
• mAb Therapeutics for Alzheimer Disease Unlikely to Be Fully Successful, According to GEN Poll
  
• GE Healthcare, Karolinska University Ally to Enable Routine Application of Cell Therapies
  
• GE Healthcare, Affibody to Develop Her2 Imaging Agent for Breast, Gastric Cancers
  
• GE Healthcare, BGI Explore Stem Cell Genetics with a View to Drug Discovery Assays
  
• Genentech Taps AC Immune in Second Alzheimer Drug Development Deal
  
• AstraZeneca Acquires Neurodegenerative Disease Assets and Establishes Research Consortium
  
• Pfizer-Janssen Alzheimer's Treatment Misses Phase III Endpoints
  
• Alzheimer's Disease Antibody Bombs
  
• Ab Fragment Imaging Firm Signs Singapore Deal
  
• Blood Test Detects Alzheimer’s and Early Cognitive Decline
  
• Fragment-Based Drug Discovery for Alzheimer’s